Mallinckrodt Sues FDA Over Methylphenidate

Mallinckrodt Sues FDA Over Methylphenidate

Mallinckrodt is a pharmaceutical company with U.S. headquarters in St. Louis, Missouri. One of their products is the generic drug Methylphenidate HCl Extended-Release (ER); methylphenidate is known as Ritalin or Concerta in some branded versions, and is prescribed for the fraudulent diagnosis of ADHD.

According to the St. Louis Business Journal, “the FDA informed [Mallinckrodt] that its methylphenidate ER hydrochloride tablets might not be therapeutically equivalent to Concerta. This means that while the drugs are still approved by the FDA, the agency won’t recommend them as automatic substitutions for Concerta.”

In response, as this FDA action is likely to negatively impact sales of the drug, Mallinckrodt is suing the FDA, claiming that the reclassification of this drug is unwarranted.

While we applaud the FDA for downgrading the status of this drug, we’d like to point out that ADHD is a fictitious disease and methylphenidate is a harmful and addictive psychotropic drug.

Anything that the FDA or Mallinckrodt says about this issue is a red herring, as the actual truth of the matter is that there is no such thing as ADHD, methylphenidate is bad for you, and there are many non-drug alternatives for the symptoms falsely attributed to ADHD.

Perhaps you know someone who says that their child is doing much better since they started taking methylphenidate. A proper response goes something like this: “I’m glad you and your child are doing better, and that your child has not experienced the horrible side effects that many others have experienced. Sometimes real physical conditions can produce similar mental symptoms to the ones your child may be experiencing. A full searching clinical examination by a competent, non-psychiatric, medical doctor might be helpful.”

Then refer the person here to the CCHR STL web page about ADHD.

This entry was posted in Big Muddy River Newsletter and tagged , , , . Bookmark the permalink.

Leave a Reply